Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material - Call Transcript

May 18, 2021 / 12:30PM GMT
Release Date Price: R$21.99 (+11.00%)
Operator

Good morning, and welcome to the Sarepta Therapeutics conference call and webcast for the clinical update for study SRP-9001-103 12-Week Expression and Safety Data Using Commercially Representative Material. (Operator Instructions) As a reminder, today's program is being recorded.

Now I will turn the call over to Mr. Doug Ingram, President and CEO, for opening remarks.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you. Good morning, and thank you for joining us for the report out from our 11 patient cohort update, our study to characterize our DMD gene therapy 9001 using our commercial process material.

Now before I turn the call over to Dr. Rodino-Klapac, let me contextualize these results. I have said before, and I will repeat it here. It is difficult to overstate the importance of this data. Indeed, these results are one of the most significant ones yet in Sarepta's history and with the benefit of hindsight, I believe, may be among the most seminal moments in the treatment of Duchenne muscular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot